[{"id":"22763cd5-04a0-4c19-8ce3-8bad45fab6c6","acronym":"CA209-8TX","url":"https://clinicaltrials.gov/study/NCT02960230","created_at":"2021-01-19T13:10:42.375Z","updated_at":"2025-02-25T14:36:49.894Z","phase":"Phase 1/2","brief_title":"H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas","source_id_and_acronym":"NCT02960230 - CA209-8TX","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02:01 • H3.3K27M • HLA-A*02 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • H3.3K27M • HLA-A*02 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 11/18/2016","start_date":" 11/18/2016","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-01-22"},{"id":"464500ff-e8fe-41f5-868c-2b492ff3e949","acronym":"GCC-16047","url":"https://clinicaltrials.gov/study/NCT02834052","created_at":"2021-01-18T13:54:28.786Z","updated_at":"2025-02-25T16:04:58.190Z","phase":"Phase 1/2","brief_title":"Pembrolizumab + Poly-ICLC in MRP Colon Cancer","source_id_and_acronym":"NCT02834052 - GCC-16047","lead_sponsor":"Asha Nayak","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 01/10/2018","start_date":" 01/10/2018","primary_txt":" Primary completion: 07/29/2022","primary_completion_date":" 07/29/2022","study_txt":" Completion: 07/29/2022","study_completion_date":" 07/29/2022","last_update_posted":"2024-06-07"},{"id":"acb3cec9-0b88-4c6f-817b-e0033a486f8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03734692","created_at":"2024-06-08T04:12:57.198Z","updated_at":"2025-02-25T16:08:36.350Z","phase":"Phase 1/2","brief_title":"Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer","source_id_and_acronym":"NCT03734692","lead_sponsor":"Robert Edwards","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Ampligen (rintatolimod)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/28/2019","start_date":" 01/28/2019","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-05"},{"id":"8e13ae6f-2afc-43dc-b06c-933f9e190424","acronym":"","url":"https://clinicaltrials.gov/study/NCT04093323","created_at":"2023-11-30T22:15:48.537Z","updated_at":"2024-07-02T16:35:00.203Z","phase":"Phase 2","brief_title":"Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma","source_id_and_acronym":"NCT04093323","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CD8","pipe":" | ","alterations":" CD8 positive","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 08/22/2025","primary_completion_date":" 08/22/2025","study_txt":" Completion: 08/22/2025","study_completion_date":" 08/22/2025","last_update_posted":"2024-05-30"},{"id":"419c5914-39f8-4485-aeac-7765e3d16495","acronym":"HAITEN-ICI","url":"https://clinicaltrials.gov/study/NCT06064279","created_at":"2023-10-03T19:11:18.305Z","updated_at":"2024-07-02T16:35:06.817Z","phase":"Phase 1/2","brief_title":"Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC","source_id_and_acronym":"NCT06064279 - HAITEN-ICI","lead_sponsor":"VA Office of Research and Development","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 06/24/2024","start_date":" 06/24/2024","primary_txt":" Primary completion: 06/22/2026","primary_completion_date":" 06/22/2026","study_txt":" Completion: 04/04/2028","study_completion_date":" 04/04/2028","last_update_posted":"2024-04-30"},{"id":"8f8e9487-9ee4-4fb4-9fb0-f22de3968e90","acronym":"NF111","url":"https://clinicaltrials.gov/study/NCT04544007","created_at":"2021-01-18T21:44:13.649Z","updated_at":"2024-07-02T16:35:14.441Z","phase":"Phase 2","brief_title":"A Phase II Trial of Poly-ICLC for Low-Grade Gliomas","source_id_and_acronym":"NCT04544007 - NF111","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/15/2021","start_date":" 12/15/2021","primary_txt":" Primary completion: 02/15/2026","primary_completion_date":" 02/15/2026","study_txt":" Completion: 02/15/2027","study_completion_date":" 02/15/2027","last_update_posted":"2024-03-15"},{"id":"3179b0f4-ea2a-4800-a780-ec771c8348bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06218303","created_at":"2024-01-23T18:20:49.964Z","updated_at":"2024-07-02T16:35:15.510Z","phase":"Phase 1","brief_title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","source_id_and_acronym":"NCT06218303","lead_sponsor":"Finn, Olivera, PhD","biomarkers":" MUC1","pipe":"","alterations":" ","tags":["MUC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • anastrozole • exemestane • Hiltonol (poly-ICLC)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/07/2024","start_date":" 02/07/2024","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2024-03-08"},{"id":"39c6b350-3479-44ce-a2c9-487a64f9b6ef","acronym":"MEL60","url":"https://clinicaltrials.gov/study/NCT02126579","created_at":"2021-01-29T07:06:15.841Z","updated_at":"2024-07-02T16:35:17.147Z","phase":"Phase 1/2","brief_title":"Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists","source_id_and_acronym":"NCT02126579 - MEL60","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD8 • IFNG","pipe":"","alterations":" ","tags":["CD8 • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 11/20/2019","primary_completion_date":" 11/20/2019","study_txt":" Completion: 05/05/2021","study_completion_date":" 05/05/2021","last_update_posted":"2024-02-28"},{"id":"888b5254-e6dd-48b6-9b64-58ed9e870a5a","acronym":"KEYNOTE-B77","url":"https://clinicaltrials.gov/study/NCT04570332","created_at":"2021-01-18T21:49:33.587Z","updated_at":"2025-02-25T16:10:40.165Z","phase":"Phase 2","brief_title":"BO-112 With Pembrolizumab in Unresectable Malignant Melanoma","source_id_and_acronym":"NCT04570332 - KEYNOTE-B77","lead_sponsor":"Highlight Therapeutics","biomarkers":" BRAF • CD4","pipe":"","alterations":" ","tags":["BRAF • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • polyinosinic:polycytidylic acid (BO-112)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/30/2020","start_date":" 12/30/2020","primary_txt":" Primary completion: 10/03/2023","primary_completion_date":" 10/03/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-01-29"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"},{"id":"fd91fe18-af69-409c-a905-0f8aee67d795","acronym":"","url":"https://clinicaltrials.gov/study/NCT01130077","created_at":"2021-01-18T04:29:21.248Z","updated_at":"2024-07-02T16:35:30.493Z","phase":"Phase 1","brief_title":"A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas","source_id_and_acronym":"NCT01130077","lead_sponsor":"James Felker","biomarkers":" IFNG","pipe":" | ","alterations":" HLA-A2 positive","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-03"},{"id":"12fc1d17-0a06-4691-bf0b-18767b9a6e88","acronym":"Mel66","url":"https://clinicaltrials.gov/study/NCT04364230","created_at":"2021-01-18T21:05:35.842Z","updated_at":"2024-07-02T16:35:33.934Z","phase":"Phase 1/2","brief_title":"Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)","source_id_and_acronym":"NCT04364230 - Mel66","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" BRAF • CD4 • FOXP3","pipe":"","alterations":" ","tags":["BRAF • CD4 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/28/2020","start_date":" 09/28/2020","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-10-11"},{"id":"809a0473-89c4-4bc7-8faf-bd2441b7e0a3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549833","created_at":"2021-01-18T12:20:05.485Z","updated_at":"2024-07-02T16:35:34.594Z","phase":"Phase 1","brief_title":"Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma","source_id_and_acronym":"NCT02549833","lead_sponsor":"Jennie Taylor","biomarkers":" CD8 • CXCL10 • CD4","pipe":" | ","alterations":" CXCL10 expression","tags":["CD8 • CXCL10 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCL10 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GBM6-AD • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 10/17/2016","start_date":" 10/17/2016","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2023-10-05"},{"id":"59bdfa97-7b2e-46bf-97c1-23ab33821d5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081389","created_at":"2021-01-18T19:59:01.001Z","updated_at":"2024-07-02T16:35:37.452Z","phase":"Phase 1","brief_title":"Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer","source_id_and_acronym":"NCT04081389","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PGR","pipe":" | ","alterations":" ER positive + PGR positive • PGR positive","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • daunorubicin • Intron A (interferon α-2b) • Ampligen (rintatolimod) • celecoxib oral • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 05/24/2022","primary_completion_date":" 05/24/2022","study_txt":" Completion: 02/27/2023","study_completion_date":" 02/27/2023","last_update_posted":"2023-09-11"},{"id":"d94de171-8220-41f2-8706-22ba38f8e320","acronym":"ETAPA I","url":"https://clinicaltrials.gov/study/NCT05283109","created_at":"2022-03-16T15:54:21.194Z","updated_at":"2024-07-02T16:35:37.647Z","phase":"Phase 1","brief_title":"ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM","source_id_and_acronym":"NCT05283109 - ETAPA I","lead_sponsor":"Mustafa Khasraw, MBChB, MD, FRCP, FRACP","biomarkers":" MGMT • BIRC5","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT • BIRC5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • P30-EPS"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 08/30/2023","start_date":" 08/30/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-09-08"},{"id":"ffd3bec8-4631-4c1a-ba0b-bb98180f81ac","acronym":"AM-003","url":"https://clinicaltrials.gov/study/NCT04116320","created_at":"2021-01-18T20:07:14.839Z","updated_at":"2024-07-02T16:35:40.797Z","phase":"Phase 1","brief_title":"Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors","source_id_and_acronym":"NCT04116320 - AM-003","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zyclara (imiquimod) • Hiltonol (poly-ICLC)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 11/21/2019","start_date":" 11/21/2019","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2023-08-07"},{"id":"ec6f64d7-9168-4070-b725-2438d52a971d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01188096","created_at":"2021-01-18T04:45:03.863Z","updated_at":"2024-07-02T16:35:45.912Z","phase":"Phase 2","brief_title":"A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas","source_id_and_acronym":"NCT01188096","lead_sponsor":"Wake Forest University Health Sciences","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 08/01/2010","start_date":" 08/01/2010","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2023-06-12"},{"id":"112a8f53-b48b-4fcf-ab56-3185a8febfbf","acronym":"","url":"https://clinicaltrials.gov/study/NCT04379518","created_at":"2021-01-18T21:09:01.336Z","updated_at":"2024-07-02T16:35:53.963Z","phase":"Phase 1/2","brief_title":"Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients","source_id_and_acronym":"NCT04379518","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Intron A (interferon α-2b) • Ampligen (rintatolimod)"],"overall_status":"Suspended","enrollment":" Enrollment 64","initiation":"Initiation: 11/17/2020","start_date":" 11/17/2020","primary_txt":" Primary completion: 11/17/2023","primary_completion_date":" 11/17/2023","study_txt":" Completion: 11/17/2023","study_completion_date":" 11/17/2023","last_update_posted":"2023-03-06"},{"id":"1cfc9dae-087d-4a45-888a-feae0e1a43ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT02166905","created_at":"2021-01-18T10:05:33.255Z","updated_at":"2024-07-02T16:35:54.811Z","phase":"Phase 1/2","brief_title":"DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission","source_id_and_acronym":"NCT02166905","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CTAG1B • CD4 • CTAG2","pipe":"","alterations":" ","tags":["CTAG1B • CD4 • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e epacadostat (INCB024360) • Hiltonol (poly-ICLC) • rasdegafusp alfa (CDX-1401)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/10/2014","start_date":" 10/10/2014","primary_txt":" Primary completion: 08/20/2020","primary_completion_date":" 08/20/2020","study_txt":" Completion: 08/20/2020","study_completion_date":" 08/20/2020","last_update_posted":"2023-02-24"},{"id":"a59f2e7d-773d-4044-b655-2dd3f2f04a4f","acronym":"IMA950-106","url":"https://clinicaltrials.gov/study/NCT03665545","created_at":"2021-01-18T17:59:08.870Z","updated_at":"2024-07-02T16:35:58.554Z","phase":"Phase 1/2","brief_title":"Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma","source_id_and_acronym":"NCT03665545 - IMA950-106","lead_sponsor":"University Hospital, Geneva","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*02:01","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/25/2018","start_date":" 10/25/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-12-26"},{"id":"e90993ce-49dc-4133-b54d-0fb1b11af01b","acronym":"","url":"https://clinicaltrials.gov/study/NCT00616941","created_at":"2021-01-29T06:58:11.865Z","updated_at":"2024-07-02T16:36:02.662Z","phase":"Phase 1","brief_title":"Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT00616941","lead_sponsor":"Ludwig Institute for Cancer Research","biomarkers":" CD8 • IFNG • CTAG1B • CD4","pipe":"","alterations":" ","tags":["CD8 • IFNG • CTAG1B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 03/01/2008","start_date":" 03/01/2008","primary_txt":" Primary completion: 06/01/2011","primary_completion_date":" 06/01/2011","study_txt":" Completion: 06/01/2011","study_completion_date":" 06/01/2011","last_update_posted":"2022-10-11"},{"id":"f636bd6e-d960-4b98-8bc3-4153df68b48f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02334735","created_at":"2021-01-29T07:07:33.888Z","updated_at":"2024-07-02T16:36:03.853Z","phase":"Phase 2","brief_title":"A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence","source_id_and_acronym":"NCT02334735","lead_sponsor":"Nina Bhardwaj","biomarkers":" CD8 • CTAG1B • CD4","pipe":"","alterations":" ","tags":["CD8 • CTAG1B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 07/15/2020","primary_completion_date":" 07/15/2020","study_txt":" Completion: 07/15/2020","study_completion_date":" 07/15/2020","last_update_posted":"2022-09-15"},{"id":"781e1446-19c4-44c8-8cfb-545a6ecf087a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03262103","created_at":"2021-01-29T07:15:21.641Z","updated_at":"2024-07-02T16:36:04.156Z","phase":"Phase 1","brief_title":"Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer","source_id_and_acronym":"NCT03262103","lead_sponsor":"Ashutosh Kumar Tewari","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 06/16/2017","start_date":" 06/16/2017","primary_txt":" Primary completion: 05/06/2022","primary_completion_date":" 05/06/2022","study_txt":" Completion: 05/06/2022","study_completion_date":" 05/06/2022","last_update_posted":"2022-09-10"},{"id":"a6ab7702-d3f8-4abb-8ca2-2914ef3e190d","acronym":"Noelia","url":"https://clinicaltrials.gov/study/NCT05265650","created_at":"2022-03-03T13:28:18.563Z","updated_at":"2024-07-02T16:36:07.185Z","phase":"Phase 1/2","brief_title":"Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC","source_id_and_acronym":"NCT05265650 - Noelia","lead_sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","biomarkers":" EGFR • ALK • CD4","pipe":"","alterations":" ","tags":["EGFR • ALK • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/13/2022","start_date":" 06/13/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-07-19"}]